-
Product Insights
Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Progressive Multiple Sclerosis (PPMS) - Drugs In Development, 2023’, provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Drugs In Development, 2023’, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Glatiramer Acetate ER in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glatiramer Acetate ER in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glatiramer Acetate ER in Relapsing Remitting Multiple...
-
Sector Analysis
Multiple Sclerosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030
Multiple Sclerosis Market Report Overview Multiple sclerosis (MS) disease-modifying therapies (DMTs) market size across the 7MM was valued at $18.9 billion in 2020 and is expected to achieve a CAGR of more than 4% during 2020-2030. Multiple Sclerosis Market Outlook, 2020-2030 ($ Billion) To gain more information about the multiple sclerosis market forecast, download a free report sample The multiple sclerosis market research report provides an analysis of the current and future market competition in the global MS therapeutics market....
-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – glatiramer acetate ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry glatiramer acetate ER Drug Details Glatiramer acetate ER is under development for the treatment...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...
-
Product Insights
Blepharospasm Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Blepharospasm Global Clinical Trials Review, H1, 2017" provides an overview of Blepharospasm clinical trials scenario. This report provides top line data relating to the clinical trials on Blepharospasm. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Cervical Dystonia Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Cervical Dystonia Global Clinical Trials Review, H1, 2017" provides an overview of Cervical Dystonia clinical trials scenario. This report provides top line data relating to the clinical trials on Cervical Dystonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Blepharospasm Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Blepharospasm Global Clinical Trials Review, H2, 2016" provides an overview of Blepharospasm clinical trials scenario. This report provides top line data relating to the clinical trials on Blepharospasm. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...